Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double Blinded, Randomized, Active Drug Comparative, Multi-center, Phase Ⅳ Clinical Study to Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients of the Knee.

NCT02049606 is registered in ClinicalTrials.gov with PMG Pharm Co., Ltd as lead sponsor.

NCT NCT02049606
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02049606 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double Blinded, Randomized, Active Drug Comparative, Multi-center, Phase Ⅳ Clinical Study to Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients of the Knee.
Lead sponsor
PMG Pharm Co., Ltd
Phase
Phase 4
Overall status
Completed
Start date
February 24, 2014
Completion date
May 30, 2016
Enrollment
134 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis of the knee